During Friday’s Morning trade, Shares of T2 Biosystems Inc (NASDAQ:TTOO), gained 7.94% to $11.01.
T2 Biosystems, declared that John McDonough, president and chief executive officer, and Moe Castonguay, chief financial officer, are planned to attend and present at the following forthcoming investor conferences:
- The Stifel Healthcare Conference on Wednesday, November 18, 2015 at 8:45 a.m. ET in New York City.
- The Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 19, 2015 at 10:30 a.m. ET in New York City.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, counting whole blood, plasma, serum, saliva, sputum, and urine.
Shares of Tobira Therapeutics Inc (NASDAQ:TBRA), inclined 3.92% to $10.08, during its current trading session.
Tobira Therapeutics, stated business highlights and financial results for the third quarter of 2015.
“We are making excellent progress on CENTAUR, our Phase 2b study of cenicriviroc for the treatment of NASH and liver fibrosis. CENTAUR is a well-powered large Phase 2b NASH study that has accomplished enrollment and exclusively enrolled patients at greater risk of progression to cirrhosis. The study was designed to comprise key secondary endpoints that may be suitable for registration under accelerated approval. We are happy to confirm that we remain on track to report topline one-year results in the third quarter of 2016,” said Laurent Fischer, M.D., Tobira’s chief executive officer. “Investigators in the CENTAUR study have begun to perform liver biopsies for the one-year primary endpoint, thereby reaching an important milestone for the CENTAUR study, patients, caregivers and Tobira.
“Additionally, at the AASLD Annual Meeting starting this weekend, Tobira will be presenting early combination data with cenicriviroc plus pioglitazone. We plan to develop cenicriviroc both as a single agent and as a foundation for future combination therapies in NASH. Cenicriviroc’s anti-inflammatory and anti-fibrogenic mechanism, once-daily dosing and well-established safety profile make it an ideal product candidate to develop as a single agent and in combination with metabolically targeted agents. We are committed to developing the full potential of cenicriviroc, to fully address the unmet need for patients at risk of progression to liver cirrhosis or cancer.”
Tobira Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis, and human immunodeficiency virus (HIV-1).
Finally, Shares of Points International Ltd (USA) (NASDAQ:PCOM), lost -3.98%, and is now trading at $9.16.
Points, declared that Anthony Lam, Vice President and Chief Financial Officer will depart the Company effective November 20, 2015, in order to pursue other opportunities.
Rob MacLean, Chief Executive Officer, said, “Since joining Points in 2007, Anthony has been an important member of the team. Anthony has led our finance and accounting organization, counting legal and investor relations, during a period of rapid growth and played a central role in taking the company public on NASDAQ. I want to thank Anthony for his dedication and commitment to Points and wish him continued success in his future endeavors.”
Points has initiated a comprehensive search for a permanent replacement and has engaged an interim CFO to ensure an orderly transition period.
Points International Ltd. provides ecommerce and technology services to loyalty program operators primarily in the United States, Europe, and Canada. It provides various white label or private branded ecommerce services, such as the online sale of loyalty currency direct to program members in order for the members to top-up their accounts to reach a redemption threshold or as a gift for friends and family members; and the online transfer of pre-existing loyalty currency from one member into another member’s account, primarily a family member or friend, as another means of enabling that other member to accumulate sufficient miles or points to reach a redemption threshold.